Evidence map›Paper›PMID 40627005›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2025

Four-year durability of the Myval balloon-expandable transcatheter aortic valve.

Akash Jain, John Jose, Matteo Montorfano, Henrik Nissen, Pedro Martin, Ashok Seth, Kresimir Stambuk, Gunasekaran Sengottuvelu, Mussayev Abdurashid, Mario García-Gómez and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The new balloon-expandable Myval transcatheter heart valve: only good news?EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Akash JainCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
John JoseChristian Medical College, Vellore, India.
Matteo MontorfanoSchool of Medicine, Vita-Salute San Raffaele University, Milan, Italy and Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Henrik NissenOdense University Hospital, Odense, Denmark.
Pedro MartinHospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain.
Ashok SethFortis Escorts Heart Institute, New Delhi, India.
Kresimir StambukMagdalena Clinic for Cardiovascular Diseases, Zagreb, Croatia.
Gunasekaran SengottuveluApollo Hospital, Chennai, India.
Mussayev AbdurashidNational Research Cardiac Surgery Center, Astana, Kazakhstan.
Mario García-GómezCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Clara Fernandez-CordónCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Marcelo RodriguezCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Mathias D JorgensenOdense University Hospital, Odense, Denmark.
Alberto CampoCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Ana SerradorCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Silvia Vallinas-HernandezCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Manuel Carrasco-MoralejaCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Alberto San RománCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
Ignacio J Amat-SantosCardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Myval series is the first commercially available balloon-expandable transcatheter aortic valve implantation (TAVI) system designed as an alternative to the SAPIEN series. The LANDMARK trial recently demonstrated its non-inferiority compared to contemporary systems. However, the long-term durability of the Myval series remains unknown.

aimsWe aimed to evaluate the 4-year durability of the Myval series using Valve Academic Research Consortium (VARC)-3-defined endpoints.

methodsWe carried out a multicentre ambispective study of patients with severe aortic stenosis who underwent TAVI with the Myval series between December 2017 and April 2020. Baseline characteristics were prospectively recorded in a dedicated database. Clinical and echocardiographic follow-up was performed at 4 years. Outcomes included haemodynamic valve deterioration (HVD), bioprosthetic valve failure (BVF), and patient-prosthesis mismatch (PPM) as defined by the VARC-3 criteria, assessed at a central echocardiography laboratory.

resultsA total of 366 patients from 9 institutions were included, all of whom completed 4-year follow-up or were followed up until death. The 4-year survival rate was 81.8%, with residual ≥moderate aortic regurgitation observed in 9.2% of patients. BVF criterion 1 (symptomatic valve failure) occurred in 3.3%, while no cases of BVF criteria 2 or 3 were reported. Stage 2 HVD was observed in 9.7% of patients and stage 3 HVD in 0.7% at 4 years. Moderate and severe PPM were identified in 3.6% and 2.1% of patients at 1 year, respectively.

conclusionsIn a real-world cohort, 4-year outcomes with the balloon-expandable Myval series demonstrated acceptable valve durability, low haemodynamic deterioration, and comparable performance to contemporary TAVI systems.

Indexed as

Aortic ValveAortic Valve StenosisHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementAgedAged, 80 and overBioprosthesisFemaleHemodynamicsHumansMaleProsthesis DesignProsthesis FailureTime FactorsTreatment Outcome

Identifiers

PMID40627005
PMCPMC12207338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.